Skin Cancer/Melanoma

New Targets May Improve the Treatment of Rare Skin Cancer

June 16, 2021

While merkel cell carcinoma (MCC) tends to have poor prognoses and limited treatment options, promising response rates with checkpoint inhibitors may pave the way for better treatment for the rare skin cancer.

FDA Approves Cemiplimab for Advanced Basal Cell Carcinoma

February 09, 2021

The FDA approved cemiplimab-rwlc as the first immunotherapy for use in patients with advanced basal cell carcinoma that has previously been treated with a hedgehog pathway inhibitor (HHI) or for whom a HHI is not appropriate.